



Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: AMRN

| | |
|---------------|----------------------------|
| Last Trade: | 4.04 |
| Trade Time: | 4:00 PM ET Jan 22, 2018 |
| Change: | 0.07 (+1.763%) |
| Day Range | 3.97 - 4.12 |
| 52-Week Range | 2.81 - 4.47 |
| Volume | 2,027,646 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 17, 2018

[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)

Jan 4, 2018

[Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook](#)

Dec 19, 2017

[Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018](#)

Dec 18, 2017

[Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco](#)

Nov 14, 2017

[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)